Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CanARY trial of cannabidiol for ultra-high risk of psychosis
ACTRN12621000349842Phase 3Recruiting
- Sponsor
- Orygen
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in Clinical high risk for psychosis (CHR) and Schizophrenia Spectrum Disorders (SSD) (3 arms), sponsored by Orygen. Primary endpoint: Severity of positive psychotic symptoms. Started Jun 2022; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
Clinical high risk for psychosis (CHR)Schizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on ACTRN12621000349842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000349842.